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Acute myeloid leukemia (AML) is an aggressive disease that originates in the bone marrow from malignant transformation of a myeloid progenitor cell. AML can occur at any age but primarily affects the elderly, with the average age at diagnosis of 72 years and three quarters of patients diagnosed after the age of sixty 1 . Despite existing cytotoxic treatments directly targeting the leukemic cell two-thirds of younger adults and 90% of older adults will die of their disease 2 . Moreover, current aggressive chemotherapy regimens are often poorly tolerated by the older less fit patients. Improved outcomes are expected to be achieved through novel therapies which are developed from an improved understanding of the biology of the disease.
AML blasts cultured in vitro undergo high levels of apoptosis, however the tumor rapidly proliferates in vivo demonstrating that the tissue microenvironment plays a fundamental role in the development of AML disease 3, 4 . The bone marrow microenvironment consists of many cell types not directly involved in haematopoiesis. These include endothelial cells; osteoclasts; osteoblasts; adipocytes and fibroblasts 5 , which are broadly classed as bone marrow stromal cells (BMSCs) and have previously been shown to support AML survival and contribute to chemotherapy resistance 6 .
In general cancer cells depend on aerobic glycolysis to generate ATP, as hypothesised by Warburg in 1956 7 and this is thought to be due to activation of oncogenes that promote glycolysis 8 . However the metabolism of AML blasts differs from most other cancers in so much as AML is primarily dependent on mitochondrial oxidative phosphorylation for survival 9 . It is also established that AML cells have higher mitochondria levels compared to non-malignant haematopoietic stem cells 10, 11 , which is entirely consistent with the observations that the tumor is dependent on a mitochondrial ATP production pathway. This proposes a key question; are the additional mitochondria in the AML blasts generated within the tumor cell or have they been acquired?
For a long time mitochondria were thought to be retained in their somatic cell for their lifetime, however in 2004 the Gerdes lab showed that mitochondria can be transferred between cells 12 . The main cell type in the bone marrow microenvironment, BMSC have been shown to donate their mitochondria to lung 4 epithelial cells preventing acute lung injury 13 . This would suggest that BMSC have the capacity to donate their mitochondria within the bone marrow niche. In the present study we look to identify if and how BMSC transfer their mitochondria to AML blasts. Furthermore, we evaluate the mechanisms controlling the increase in mitochondria in AML blasts and finally whether blocking this process is specifically lethal to the tumor but not to the counterpart non-malignant hematopoietic progenitor cells in the bone marrow.
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Methods

Materials
Anti- CD45-FITC, anti-CD33-APC, anti-CD90-FITC, anti-CD73-PE, anti-CD105-APC antibodies and CD34 microbeads were purchased from Miltenyi Biotec (Auburn, CA, USA). CellROX green, MitoTracker Green FM and Vybrant Dil stain were purchased from ThermoFisher (Waltham, MA, USA). Human Mitochondrial DNA (mtDNA)
Monitoring Primer Set and the rLV.EF1.mCherry-mito-9 Lentivirus were purchased from Clontech Takara Bio Europe (Saint-Germain-en-Laye, France). Murine mitochondrial to nuclear DNA ratio kit was purchased from Detroit R&D (Detroit, MI, USA). All other reagents were obtained from Sigma-Aldrich (St Louis, MO, USA), unless otherwise indicated.
Primary cell culture and differentiation
Primary AML blasts were obtained from patient bone marrow following informed consent and under approval from the UK National Research Ethics Service (LRCEref07/H0310/146). Non-malignant CD34+ haematopoietic stem cells (HSC)
were obtained from peripheral blood venesections from normal patients. AML cell isolation was carried out by density gradient centrifugation using Histopaque (SigmaAldrich) and cell type was confirmed by flow cytometry as previously described 14 .
CD34+ HSC were isolated using density gradient centrifugation and CD34+ microbeads (Miltenyi Biotec). Bone marrow stromal cells (BMSC) were isolated by adherence to tissue culture plastic and were then expanded in Dulbecco's Modified
Eagle's Medium (DMEM) containing 20% foetal bovine serum (FBS) and supplemented with 1% penicillin-streptomycin (Hyclone, Life Sciences). BMSC markers were confirmed using flow cytometry for expression of CD90+, CD73+, CD105+ and CD45-.
Flow cytometry
For this study we used the CyFlow Cube 6 (Sysmex, Milton Keynes, UK). Cells were incubated for 5 minutes with the FCR receptor blocker (MIltenyi Biotec, Cat. 130-059-901) and then stained with isotype controls or test antibodies (Miltenyi Biotec).
Gates were set to the appropriate isotype control.
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Mitochondrial Mass determination
To assess mitochondrial DNA copy number we performed direct qRT-PCR of primary cells using Terra qPCR Direct Polymerase mix and Human Mitochondrial DNA (mtDNA) Monitoring Primer Set (Clontech Takara Bio Europe) according to manufactures protocols.
MitoTracker based mitochondrial transfer assay
Human primary BMSC were stained with 200nM MitoTracker Green FM for 1 hour.
Primary AML blasts were also stained with 200nM MitoTracker Green FM for 30
mins. Both cell types were washed three times in phosphate buffered saline (PBS) to remove the unbound probe. Stained AML blasts were added to stained BMSC at a 5:1 ratio for 24 hours. Stained AML were also grown in mono-culture for 24 hours as a control. After incubation AML were removed from BMSC and MitoTracker fluorescence in these cells was analysed using the CyFlow Cube 6 flow cytomter (Sysmex, Milton Keynes). This assay was used to quantify mitochondrial transfer to determine the stimulus mechanism, the difference in MitoTracker fluorescence between AML blasts grown with and without BMSC provided a baseline mitochondrial transfer. A pharmacological screen was carried out, whereby numerous drugs and pathway inhibitors were added to the MitoTracker based coculture, glutathione, hydrogen peroxide and diphenyleneiodonium chloride (Sigma Aldrich) were used further with additional patient AML blasts.
AML xenograft model
All in-vivo studies were carried out following approvals from the UK home office and Mice injected with OCI-AML3-luc cells were monitored via in vivo bioluminescent imaging (Bruker, Coventry UK). At pre-defined humane end points mice were sacrificed (6-12 weeks post injection), bone marrow isolated and engraftment 7 determined using human CD33 and CD45 expression. Human AML blasts were purified from the heterogeneous bone marrow by MACS using CD45 microbeads.
This purified human AML blast population was used for the PCR and agarose gel electrophoresis. Levels of mitochondria in the purified OCI-AML3-luc populations was achieved using MitoTracker Green FM staining and flow cytometry.
Murine mitochondrial DNA detection
Murine mitochondrial DNA detection was used to determine if inter-species mitochondrial transfer occurred from murine BMSC to human AML blasts. This method was used for both the in vitro culture and in vivo study. DNA from the purified human AML blasts was extracted using the GenElute mammalian DNA miniprep kit.
8ng of DNA was added to the PCR reaction containing Sybr green and murine primers provided in the Detroit R&D kit. PCRs were amplified for 40 cycles (95°C/15 seconds, 60°C/60 seconds) on a Roche 96-well LightCycler480. PCR products were run on a 1.25% agarose gel at 100V for 1 hour. Detection was performed by
Chemdoc-It2 Imager (UVP) and analysed using ImageJ.
Fluorescence and Confocal Microscopy
Primary human BMSC were transduced with a rLV.EF1. mCherry-Mito-9 Lentivirus and were cultured with primary AML blasts for between 72 hours and 3 weeks. Live confocal images were acquired on Zeiss LSM 800 Axio Observer.Z1 confocal microscope with 40X and 63X water objectives (Carl Zeiss).
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) and CellROX assays
BMSC after a 24h co-culture with primary AML blasts were stained with 20µM washed with PBS and analysed using confocal microscopy.
Lentiviral transduction
NOX-2 shRNA glycerol stock was purchased from Sigma Aldrich (TRCN0000064588). Lentivirus particles generated using this construct were produced as previously described 15 . Lentiviral stocks were concentrated using Amicon® Ultra centrifugal filters and titres were determined using Lenti-X™ qRT-PCR titration kit (CloneTech). Primary AML blasts were plated at a density of 5x10 4 /well in a 24 well plate and infected with the NOX-2 lentivirus at MOI 30. NOX-2 knockdown was confirmed using qRT-PCR.
Real-time polymerase chain reaction
Reverse transcription was performed using an RNA polymerase chain reaction Messenger RNA (mRNA) expression was normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Apoptosis
Apoptosis of AML blasts and non-malignant CD34+ HSC was measured using PI/AnnexinV (eBiosciences) after co-culture with AML blasts and was quantified using flow cytometry.
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Amplex Red Superoxide Assay
The amplex red hydrogen peroxide/peroxidase assay kit was used to determine superoxide production was control KD vs NOX-2 KD AML blasts. 1x10 5 standard curve allowing superoxide quantification.
Mitochondrial Respiration
Mitochondrial respiration in AML blasts was assessed using the Seahorse XFp Analyzer, as previously described 16 , and the Seahorse XF Mito stress test kit (Agilent Seahorse Bioscience) according to manufacturer's specifications. Briefly, AML blasts were cultured with or without BMSC and then removed from co-culture and plated in poly-D-lysine (Sigma) coated assay wells at a density of 2x10 5 per well in base media containing 2.5mM glucose, 0.5mM carnitine and 5mM HEPES.
Oligomycin (2µM), FCCP (0.25µM) and Rotenone (0.5µM) were added into the injection ports. The experimental template was designed using Wave software for desktop from Seahorse Bioscience. ATP production was monitored by the CellTitreGlo assay (Promega).
Statistical analysis
We used the Mann-Whitney U test, Wilcoxon matched pairs test and paired t test to compare results between groups. The Mantel-Cox test was used to analyse KaplanMeier survival curves. Results with P < 0.05 (denoted by *), P < 0.01 (denoted by **) P < 0.001 (denoted by ***) were considered statistically significant. Results represent the mean ± Standard Deviation of 4 independent experiments. We generated statistics with Graphpad Prism 5 software (Graphpad, San Diego, CA, USA).
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Results
BMSC donate their mitochondria to leukemic blasts.
As previously reported human AML blasts have an increased mitochondrial mass compared to non-malignant CD34+ progenitor cells 10, 11 ( Figure 1A ). To determine if BMSC support the increase of mitochondria in AML we examined mitochondrial content after in-vitro co-culture. Figure 1B shows that AML increase their mitochondrial mass after co-culture with BMSC. Next we used 3 different methods to
show that BMSC transfer their mitochondria to primary human AML.
First, we assessed mitochondrial transfer between our patient derived BMSC and primary AML blasts by infecting BMSC with a rLV.EF1.mCherry-Mito-9 Lentivirus for stable production of mitochondria incorporated mCherry tagged protein. Using this we observed that primary AML blasts, after co-culture with these BMSC, acquired the mCherry fluorescence ( Figure 1C and 1D ). This demonstrates that mitochondria from the BMSC with the mCherry tag move to the AML blasts.
Second, we used MitoTracker Green FM stain to quantify mitochondria in AML after co-culture with BMSC. We incubated both BMSC and AML with MitoTracker Green FM stain for 1h. The cells were washed twice in PBS and incubated for 4 h. The cells were then co-cultured for 24 h and then measured for MitoTracker fluorescence using flow cytometry. Figure 1E shows that AML in cultured with BMSC had significantly more mitochondria than AML cells cultured alone. This was also the case for the OCI-AML3 cell line (Supplementary Figure 1A) . To begin to address whether this is a tumor specific phenomenon we repeated the experiment using nonmalignant CD34+ cells in the BMSC assay and showed no significant increase in MitoTracker fluorescence in the hematopoietic progenitor cells ( Figure 1F ). expression confirming human AML blast identity ( Figure 2B ) and Figure 2C shows that the human CD45 sorted cells were a pure population. Next we wanted to determine if the engrafted AML and subsequent CD45 purified human blasts had acquired mouse mitochondria. To do this we performed a PCR analysing mouse mitochondrial DNA and mouse genomic DNA. Figure 2D shows that AML blasts isolated from engrafted NSG mice contained mouse mitochondrial DNA but not mouse genomic DNA, this was also the case for the OCI-AML3 cell line ( Figure 2E ).
Taken together these 3 methods show that mitochondria are transferred from BMSC to leukemic blasts both in vitro and in vivo.
Mitochondria transfer occurs via leukemia derived tunnelling nanotubule (TNT)
A constant observation from live cell imaging was that AML blasts that acquire the mCherry fluorescence are in direct contact with the BMSC, this led us to investigate whether a cell-cell interaction is the way mitochondria move between the two cell types ( figure 1C ). We first hypothesised that tunnelling nanotubes (TNT) facilitate mitochondrial transfer from BMSC to AML blasts. To inhibit TNT formation we added cytochalasin B to our mCherry-Mito-9 BMSC-AML co-culture experiment. Figure 3A and 3B show that there is a significant reduction in the percentage of AML blasts that acquire the mCherry fluorescence after cytochalasin B treatment. This suggests that mitochondria from the BMSC are transferred to the AML blast via TNTs.
TNTs are functionally dynamic, so in order to visualise the transfer of mitochondria we used a fixed cell based imaging. To do this we stained AML blasts with the Vybrant lipid stain (red) and the mitochondria in BMSC cells with MitoTracker Green FM stain and then cultured the cells together for 24 hours. Following co-culture the cells were fixed and TNT formation was detected using confocal microscopy. In Figure 3C we observed green mitochondria from the BMSC in the red TNT projecting from the AML blasts.
ROS regulates the transfer of mitochondria from BMSC to leukemia blasts
It is not known what stimulates mitochondrial transfer in AML or any cancer.
Moreover, determination of the controlling stimulus is essential if this biological phenomenon is to be exploited therapeutically in the future.
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To identify the mechanism of mitochondrial transfer in AML we used a pharmacological screen in which the MitoTracker experiment described in Figure 1 was employed as a screening tool. Figure 4A shows that N-acetyl cysteine (NAC), glutathione (GSH) and diphenyleneiodonium (DPI) inhibit mitochondrial transfer. In contrast we observe that hydrogen peroxide (H 2 O 2 ), daunorubicin and cobalt chloride further enhance mitochondrial transfer from BMSC to AML blasts. In our baseline experimental conditions mitochondria did not transfer from BMSC to non-malignant CD34+ cells ( Figure 1F ). However, the addition of H 2 O 2 to the co-culture of nonmalignant CD34+ cells and BMSC co-cultures was able to induce mitochondrial transfer to the CD34+ cells. Next we wanted to determine if AML blasts are responsible for an increase in ROS levels in BMSC. To do this we analysed BMSC ROS when cultured with AML using two assays CellROX and 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) assay. Figure 4E , F and G shows that culture with AML blasts causes increased ROS levels and oxidative stress in the BMSC. Figure 4H shows that non-malignant CD34+ cells do not increase ROS levels in BMSC. Taken together these results, show that AML induced ROS stimulate mitochondrial transfer from BMSC.
AML derived NOX-2 drives mitochondrial transfer
We observed that diphenyleneiodonium (DPI) was able to inhibit mitochondrial transfer in our assays ( Figure 5A , Supplementary Figure 1B) . As DPI inhibits NOX-2, and NOX-2-derived ROS plays a critical role in mobilization and homing of nonmalignant hematpoietic stem cells 17 , we next asked whether NOX-2 derived superoxide produced by the AML was responsible for mitochondrial transfer. We knocked down NOX-2 using a lentiviral transduction ( Figure 5B ) in 4 human AML patient cell samples and the OCI-AML3 cell line. Then we analysed mitochondrial transfer to AML following NOX-2 or control shRNA knockdown. Figure 5C shows a significant reduction in mitochondrial transfer in the NOX-2 KD AML cells compared to control KD blasts, also consistent with the OCI-AML3 cell line (Supplementary Figure 1C) . To confirm that superoxide was reduced in the NOX-2 KD cells we analysed superoxide using the AmplexRED assay. Figure 5D shows that NOX-2 KD cells have significantly reduced superoxide. Next we tested if AML with NOX-2 KD could increase ROS in BMSC. Figure 5E shows that NOX-2 KD AML cells had a reduced capacity to stimulate ROS production in the BMSC compared to control KD 1 3 blasts. Finally, we tested if DPI could reduce survival of AML in culture with BMSC. Figure 5F shows that AML blast survival on BMSC is inhibited by the addition of DPI.
Moreover, DPI had little or no effect on the viability of non-malignant CD34+ cells grown in co-culture with BMSC ( Figure 5G ). Taken together in leukemic blasts NOX2 derived superoxide stimulates ROS generation in BMSC which results in mitochondrial transfer from the stroma to the tumor.
Mitochondria acquired by the AML blast are functionally active and contribute to the metabolic capacity
We next explored the function of mitochondrial transfer in relation to mitochondrial respiration. We found that after co-culture with BMSC AML blasts have increased basal and maximum mitochondrial respiration compared control cells ( Figures 6A   and 6B ). In addition, the ATP production capacity of AML blasts in co-culture with BMSC was increased compared to control cells ( Figure 6C ). This shows that mitochondria in AML after co-culture with BMSC are functional and contribute to energy requirements of the rapidly proliferating cancer cell. To determine if the mitochondria transferred are responsible for this increased respiration, we analysed the mitochondrial respiration in the control and NOX-2 knockdown primary AML blasts in co-culture with BMSC. We found that knockdown blasts had significantly reduced basal and maximum mitochondrial respiration ( Figure 6D) , showing that mitochondrial transfer has to occur in order for AML to have increased mitochondrial output when cultured with BMSC.
NOX-2 is crucial for the development of AML in an in vivo xenograft model
To analyse in the impact of NOX-2 on mitochondrial transfer and disease progression, we engrafted control KD and NOX-2 KD OCI-AML3-luc cells into NSG mice. Mice were imaged using bioluminescence at weekly intervals. These images revealed that there is reduced AML disease progression and engraftment in the bone marrow with NOX-2 KD cells compared to the control KD cells ( Figure 7A ). Disease progression was monitored until humane end point, the survival of the NOX-2 KD mice was significantly increased compared to the control KD mice ( Figure 7B ). OCI-AML3-luc reliably engrafted into NSG mice, verified by human CD45 expression confirming human AML blast identity ( Figure 7C ). Mitochondrial levels were analysed in the two cell populations pre and post engraftment into the NSG mice, using
MitoTracker Green FM. There was no difference in the mitochondrial levels between the control and NOX-2 KD pre-engraftment ( Figure 7D ). However in the purified OCI-AML3-luc cells post engraftment, the control KD cells had significantly increased mitochondrial levels compared to NOX-2 KD cells ( Figure 7E ). Taken together these results show that there is reduced mitochondrial transfer in vivo to NOX-2 KD cells compared to control KD cells. This reduces the engraftment and disease progression in these cells and enhances survival.
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Discussion
In this study we report that BMSC within the protective microenvironment of AML transfer their mitochondria to AML blasts. Furthermore, we show that mitochondria are transferred via AML-derived TNTs. We identified that AML derived ROS drives mitochondrial transfer from the BMSC to the AML. Specifically, NOX-2 derived superoxide generated from the AML causes mitochondrial transfer, shown through in vitro and in vivo studies. We were able to reduce mitochondrial transfer using both lentiviral knockdown and pharmacological inhibition of NOX2. Overall our results provide a first in cancer mitochondrial transfer mechanism, whereby the cancer cell drives transfer through increasing oxidative stress in the non-malignant donor cell.
Mitochondrial transfer is known to occur in other cancers such as breast 18 , lung 19 and melanoma 20 . Our work shows in patient derived AML blast and BMSC samples, using three in vitro methods and an in vivo model that mitochondrial transfer was also observed between the BMSC and the AML blast. The mitochondria that move to the AML are also functionally active, highlighting that the AML blast is using this biological phenomenon to its metabolic advantage. As Mitochondrial transfer has been shown to occur via TNTs in some cancers 18, 21, 22 , whereas in other disease contexts it has been shown to be via connexin-43 GAP junctions 13 . A constant observation was that AML blasts which acquired mitochondria were in contact with BMSC, therefore we first analysed whether the mitochondria could be moving via TNTs in our AML cancer setting. Through the addition of cytochalasin B to the co-culture and capturing the dynamic interactions through confocal microscopy, we report that mitochondria move from BMSC to AML blasts predominantly through TNTs. In previous literature presenting mitochondrial transfer in AML it was suggested that mitochondria moved between cells via endocytosis 23 .
Our results do not disprove this idea and it is possible a combination of the two mechanisms (or possibly more) contribute to the total mitochondria that are acquired by the AML blast. The TNT mechanism is however necessary for AML survival.
Through the pharmacological screen we highlighted that inducing ROS increased mitochondrial transfer, whereas inhibiting ROS reduced transfer. Additionally, we found that AML blasts increase oxidative stress in the BMSC. Chronic oxidative stress has been shown to aid tumour survival 24 , metastasis 25 and proliferation
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is also known that there are high levels of oxidative stress in AML 27 and that in AML disease relapse there are increased markers of oxidative stress 28 . As we have shown oxidative stress drives mitochondrial transfer, this biological phenomenon may be the underlying reason why oxidative stress promotes AML proliferation and relapse. Interestingly using H 2 O 2 we could stimulate mitochondrial transfer to nonmalignant CD34+ cells, which do not otherwise acquire mitochondria under baseline conditions, AML acts in a 'parasitic' way by generating the hypoxic conditions in the bone marrow necessary for mitochondrial transfer from stromal cells.
We show that specifically NOX-2 generated superoxide derived from the AML blasts drives the observed mitochondrial transfer, which provides a molecular target for the process. NOX-2 has an established role in immune defence whereby superoxide produced by NOX-2 on phagocytic myeloid cells destroys pathogens 29 . Overall we report a first in cancer mitochondrial transfer mechanism whereby NOX-2 derived oxidative stress drives transfer from non-malignant BMSC to AML blasts.
Moreover, we show that this mitochondrial transfer is fundamentally a part of the malignant AML phenotype. Accordingly, these results may have the ability to be 1 7 translated into other malignancies where mitochondrial transfer has previously been observed but, where the specific mechanism have yet to be elucidated. Finally, our results identify a novel therapeutic opportunity to be developed and explored for the treatment of AML. MitoTracker green FM for 1 h and washed 3 times in PBS. AML blasts and BMSC were then cocultured for 24 hours before fixation using paraformaldehyde. Cells were visualised by confocal microscopy. (50µM) AML were removed and BMSC were stained for ROS using CellROX. BMSC were visualised for ROS using fluorescence microscopy. (F) BMSC cultured alone and in co-culture with AML or treated with H 2 O 2 (50µM) AML were removed and BMSC were stained for ROS using H2DCFDA (10µM). BMSC were visualised for ROS using fluorescence microscopy or flow cytometry (G) BMSC cultured alone and in co-culture with non-malignant CD34+ cells or treated with H 2 O 2 (50µM) AML were removed and BMSC were stained for ROS using H2DCFDA (10µM). BMSC were visualised for ROS flow cytometry. 
